Analysts Set Enhabit, Inc. (NYSE:EHAB) Target Price at $8.75

Shares of Enhabit, Inc. (NYSE:EHAB) have been given an average rating of “Hold” by the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $8.75.

A number of equities analysts have recently issued reports on the stock. Leerink Partners reiterated a “market perform” rating and issued a $8.00 price target (down previously from $8.50) on shares of Enhabit in a report on Tuesday, November 19th. Jefferies Financial Group upgraded shares of Enhabit from a “hold” rating to a “buy” rating and raised their target price for the company from $8.25 to $9.50 in a report on Monday, December 9th.

Enhabit Stock Down 2.6 %

EHAB stock opened at $7.60 on Wednesday. Enhabit has a one year low of $6.85 and a one year high of $11.74. The stock has a market capitalization of $382.16 million, a PE ratio of -3.28 and a beta of 1.82. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.46 and a current ratio of 1.46. The company has a fifty day moving average of $7.81 and a 200-day moving average of $8.15.

Enhabit (NYSE:EHAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The company had revenue of $253.60 million during the quarter, compared to analysts’ expectations of $261.69 million. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. During the same quarter in the prior year, the business earned $0.03 EPS. As a group, analysts expect that Enhabit will post 0.22 EPS for the current year.

Insiders Place Their Bets

In related news, Director Stuart M. Mcguigan bought 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were acquired at an average cost of $8.81 per share, with a total value of $132,150.00. Following the completion of the transaction, the director now owns 46,810 shares of the company’s stock, valued at approximately $412,396.10. The trade was a 47.15 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jeffrey Bolton bought 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $8.69 per share, for a total transaction of $34,760.00. Following the completion of the transaction, the director now directly owns 98,144 shares of the company’s stock, valued at approximately $852,871.36. The trade was a 4.25 % increase in their position. The disclosure for this purchase can be found here. 1.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC lifted its position in Enhabit by 138.4% during the third quarter. FMR LLC now owns 3,388 shares of the company’s stock valued at $27,000 after buying an additional 1,967 shares in the last quarter. Quarry LP lifted its position in Enhabit by 242.2% during the second quarter. Quarry LP now owns 3,703 shares of the company’s stock valued at $33,000 after buying an additional 2,621 shares in the last quarter. Gladius Capital Management LP lifted its position in Enhabit by 78.2% during the third quarter. Gladius Capital Management LP now owns 6,259 shares of the company’s stock valued at $49,000 after buying an additional 2,747 shares in the last quarter. Stoneridge Investment Partners LLC purchased a new stake in shares of Enhabit during the third quarter valued at approximately $81,000. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Enhabit during the second quarter valued at approximately $93,000.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.